These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 2183815)

  • 21. Peptides mimicking selected disulfide loops in HIV-1 gp120, other than V3, do not elicit virus-neutralizing antibodies.
    Neurath AR; Strick N; Fields R; Jiang S
    AIDS Res Hum Retroviruses; 1991 Aug; 7(8):657-62. PubMed ID: 1718344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
    Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
    J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV-1MN recombinant gp120 vaccine serum, which fails to neutralize primary isolates of HIV-1, does not antagonize neutralization by antibodies from infected individuals.
    Wrin T; Nunberg JH
    AIDS; 1994 Nov; 8(11):1622-3. PubMed ID: 7848602
    [No Abstract]   [Full Text] [Related]  

  • 25. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.
    Earl PL; Sugiura W; Montefiori DC; Broder CC; Lee SA; Wild C; Lifson J; Moss B
    J Virol; 2001 Jan; 75(2):645-53. PubMed ID: 11134278
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.
    Wang S; Pal R; Mascola JR; Chou TH; Mboudjeka I; Shen S; Liu Q; Whitney S; Keen T; Nair BC; Kalyanaraman VS; Markham P; Lu S
    Virology; 2006 Jun; 350(1):34-47. PubMed ID: 16616287
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies.
    Haigwood NL; Shuster JR; Moore GK; Lee H; Skiles PV; Higgins KW; Barr PJ; George-Nascimento C; Steimer KS
    AIDS Res Hum Retroviruses; 1990 Jul; 6(7):855-69. PubMed ID: 2390335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape.
    Arendrup M; Sönnerborg A; Svennerholm B; Akerblom L; Nielsen C; Clausen H; Olofsson S; Nielsen JO; Hansen JE
    J Gen Virol; 1993 May; 74 ( Pt 5)():855-63. PubMed ID: 7684062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polyclonal antiidiotypic antibodies mimicking gp120 of HIV-1.
    Sperlagh M; Hoxie J; Maruyama H; Stefano K; Gonzales-Scarano F; Prewett M; Liang S; Matsushita S; Herlyn D
    Viral Immunol; 1994; 7(2):61-9. PubMed ID: 7531443
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interactions of polyclonal and monoclonal anti-glycoprotein 120 antibodies with oligomeric glycoprotein 120-glycoprotein 41 complexes of a primary HIV type 1 isolate: relationship to neutralization.
    Fouts TR; Trkola A; Fung MS; Moore JP
    AIDS Res Hum Retroviruses; 1998 May; 14(7):591-7. PubMed ID: 9591713
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amino acid residues of the human immunodeficiency virus type I gp120 critical for the binding of rat and human neutralizing antibodies that block the gp120-sCD4 interaction.
    McKeating JA; Thali M; Furman C; Karwowska S; Gorny MK; Cordell J; Zolla-Pazner S; Sodroski J; Weiss RA
    Virology; 1992 Sep; 190(1):134-42. PubMed ID: 1382339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Infection of vaginal and colonic epithelial cells by the human immunodeficiency virus type 1 is neutralized by antibodies raised against conserved epitopes in the envelope glycoprotein gp120.
    Furuta Y; Eriksson K; Svennerholm B; Fredman P; Horal P; Jeansson S; Vahlne A; Holmgren J; Czerkinsky C
    Proc Natl Acad Sci U S A; 1994 Dec; 91(26):12559-63. PubMed ID: 7809077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of human immunodeficiency virus type 1 glycoprotein gp120/gp41 interacting sites by the idiotypic mimicry of two monoclonal antibodies.
    Lopalco L; Longhi R; Ciccomascolo F; De Rossi A; Pelagi M; Andronico F; Moore JP; Schulz T; Beretta A; Siccardi AG
    AIDS Res Hum Retroviruses; 1993 Jan; 9(1):33-9. PubMed ID: 7678970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design.
    Pantophlet R; Wilson IA; Burton DR
    J Virol; 2003 May; 77(10):5889-901. PubMed ID: 12719582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.
    Scanlan CN; Pantophlet R; Wormald MR; Ollmann Saphire E; Stanfield R; Wilson IA; Katinger H; Dwek RA; Rudd PM; Burton DR
    J Virol; 2002 Jul; 76(14):7306-21. PubMed ID: 12072529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.
    Belshe RB; Graham BS; Keefer MC; Gorse GJ; Wright P; Dolin R; Matthews T; Weinhold K; Bolognesi DP; Sposto R
    JAMA; 1994 Aug; 272(6):475-80. PubMed ID: 7913731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monoclonal antibodies raised against covalently crosslinked complexes of human immunodeficiency virus type 1 gp120 and CD4 receptor identify a novel complex-dependent epitope on gp 120.
    DeVico AL; Rahman R; Welch J; Crowley R; Lusso P; Sarngadharan MG; Pal R
    Virology; 1995 Aug; 211(2):583-8. PubMed ID: 7544051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isolation and characterization of a novel neutralizing antibody targeting the CD4-binding site of HIV-1 gp120.
    Qiao Y; Man L; Qiu Z; Yang L; Sun Y; He Y
    Antiviral Res; 2016 Aug; 132():252-61. PubMed ID: 27387828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.